Roche still plans to make its high-density peptide microarrays available to customers in the future.

A company spokesperson told BioArray News recently that one of the Swiss company's priorities next year will be to "set up a strategic plan to best commercialize this technology." The spokesperson said that the company would be able to discuss more details once its plans are in place.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.